In short
This article discusses ongoing clinical trials for V116, a novel 21-valent pneumococcal conjugate vaccine developed by Merck & Co. Inc. These Phase 3 studies aim to assess the safety, tolerability, and immunogenicity of V116 in different populations, including adults with increased risk of pneumococcal disease, older adults, and children and adolescents at higher risk. The trials compare V116 to existing pneumococcal vaccines and evaluate its potential in preventing pneumococcal infections across various age groups and risk factors.
At a glance
- Vaccine
- V116 (21-valent pneumococcal conjugate vaccine)
- Developer
- Merck & Co. Inc.
- Study Phase
- Phase 3
- Study Populations
- 1. Adults 18-64 years with increased risk for pneumococcal disease; 2. Adults 50 years and older; 3. Children and adolescents with increased risk for pneumococcal disease
- Primary Objectives
- 1. Evaluate safety and tolerability; 2. Compare immune response to existing vaccines (e.g., PPSV23)
- Key Measurements
- 1. Adverse events (AEs); 2. Opsonophagocytic activity (OPA) geometric mean titers (GMTs); 3. Immunoglobulin G (IgG) geometric mean concentrations (GMCs)
- Inclusion Criteria
- Vary by study, but generally include specific risk conditions (e.g., diabetes, chronic liver/lung/heart/kidney disease) and vaccination history
- Exclusion Criteria
- Include recent febrile illness, certain medical conditions, recent vaccinations, and immunodeficiencies
- Administration
- Intramuscular injection, 0.5 mL dose
What is V116?
V116 is a new pneumococcal vaccine being developed to help prevent pneumococcal disease. It is also known as the Pneumococcal 21-valent Conjugate Vaccine. This vaccine is designed to protect against 21 different types (serotypes) of pneumococcal bacteria, which can cause serious infections like pneumonia, meningitis, and bloodstream infections.
How Does V116 Work?
V116 works by stimulating the body's immune system to produce antibodies against specific parts of the pneumococcal bacteria. It contains small pieces of 21 different serotypes of pneumococcal bacteria, each attached (or "conjugated") to a carrier protein called CRM197. This combination helps the immune system recognize and remember these bacterial components, allowing it to fight off future infections more effectively.
Who is V116 For?
Based on the ongoing clinical trials, V116 is being studied for use in several groups:
- Adults aged 18 to 64 years who have an increased risk of pneumococcal disease
- Adults 50 years of age or older
- Children and adolescents with increased risk of pneumococcal disease
People at increased risk for pneumococcal disease may include those with certain medical conditions such as:
- Diabetes mellitus
- Chronic liver disease
- Chronic obstructive pulmonary disease (COPD)
- Asthma
- Chronic heart disease
- Chronic kidney disease
Clinical Trials
V116 is currently being studied in several Phase 3 clinical trials. These trials are designed to evaluate the safety, tolerability, and effectiveness of the vaccine in different populations. The main goals of these studies include:
- Assessing the safety of V116 by monitoring for adverse events
- Measuring the immune response to the vaccine by looking at antibody levels
- Comparing V116 to existing pneumococcal vaccines like PPSV23 (23-valent pneumococcal polysaccharide vaccine)
Safety and Side Effects
As with any vaccine, safety is a top priority in the development of V116. The clinical trials are closely monitoring for any side effects or adverse events. Common side effects of vaccines may include:
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
- Muscle pain
- Fever
The studies are specifically looking at both local reactions (at the injection site) and systemic reactions (affecting the whole body) to ensure the vaccine's safety profile is well understood.
Administration
V116 is administered as an intramuscular injection, typically in the upper arm (deltoid muscle). The vaccine is given as a single 0.5 mL dose. This means you only need one shot to potentially get protection against the 21 types of pneumococcal bacteria included in the vaccine.
Potential Benefits
If proven safe and effective, V116 could offer several potential benefits:
- Broader protection: By targeting 21 serotypes of pneumococcal bacteria, V116 may provide wider coverage against pneumococcal infections compared to some existing vaccines.
- Single dose: The vaccine is being studied as a single-dose regimen, which could make it more convenient for patients.
- Tailored protection: By including serotypes that are common causes of pneumococcal disease in adults, V116 aims to provide targeted protection for adult populations.
- Protection for high-risk groups: The vaccine is being studied in populations at increased risk of pneumococcal disease, potentially offering important protection for vulnerable individuals.
It's important to note that while these potential benefits are promising, the final effectiveness and approved uses of V116 will depend on the results of the ongoing clinical trials and regulatory review.